2
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
2
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Thoracic
1
Plasma cell
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Melanoma
34
Neoplasms
14
Carcinoma, Non-Small-Cell Lung
10
Colorectal Neoplasms
8
Ovarian Neoplasms
7
Multiple Myeloma
6
Breast Neoplasms
6
Pancreatic Neoplasms
5
Neoplasm Metastasis
4
Hematologic Neoplasms
4
Solid Tumors
3
Neoplasms by Site
3
Lymphoma, Non-Hodgkin
3
Lung Neoplasms
3
Leukemia, Myeloid, Acute
3
Gastrointestinal Neoplasms
3
Cholangiocarcinoma
3
Brain Neoplasms
3
Urinary Bladder Neoplasms
2
Thyroid Neoplasms
2
Thyroid Carcinoma, Anaplastic
2
Thyroid Cancer, Papillary
2
Solid Tumor
2
Skin Neoplasms
2
Sarcoma
2
Prostatic Neoplasms
2
Neoplasms by Histologic Type
2
Leukemia, Myelomonocytic, Chronic
2
Gallbladder Neoplasms
2
Fallopian Tube Neoplasms
2
Interventions
Cyclophosphamide
9
Pemetrexed
6
pembrolizumab
5
fludarabine
5
Gemcitabine
5
Cisplatin
5
Carboplatin
5
ponatinib
4
atezolizumab
4
Rituximab
4
Dexamethasone
4
Bevacizumab
4
130-nm albumin-bound paclitaxel
4
Sunitinib
3
Melphalan
3
Lutetium
3
Doxorubicin
3
Bortezomib
3
tetulomab tetraxetan lu-177
2
pralsetinib
2
pomalidomide
2
osimertinib
2
napabucasin
2
isatuximab
2
fludarabine phosphate
2
ficlatuzumab
2
entrectinib
2
entinostat
2
durvalumab
2
cobimetinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms by Histologic Type
×
cobimetinib
×
Clear all
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled